TOPP5 Antibody

What is the TOP-Plus antibody testing platform?

TOP-Plus (Testing-On-a-Probe plus panel) is a versatile biosensor platform designed specifically for comprehensive antibody monitoring. It represents an advanced serological testing approach that can simultaneously measure multiple antibody parameters on a single sensor, providing a more complete assessment of humoral immune responses than traditional antibody assays.

The platform integrates multiple testing capabilities including total antibody (TAb), surrogate neutralizing antibody (SNAb), IgG, IgM, and importantly, antibody avidity measurements . This integration allows researchers to obtain a multi-dimensional view of antibody responses, which is particularly valuable for understanding the evolution of immunity over time.

How does the TOP-Plus avidity assay compare with traditional antibody testing methods?

The TOP-Plus avidity assay offers several methodological advantages over traditional antibody testing approaches:

What types of samples can be analyzed with TOP-Plus?

TOP-Plus has been validated for use with human serum samples from both previously infected individuals and vaccinated subjects. The platform has successfully been used to analyze paired samples from 80 patients at different time points (1.3 and 6.2 months after infection), demonstrating its utility for longitudinal studies .

The testing platform can effectively process individual sera on a single sensor, making it suitable for both large cohort studies and personalized monitoring of immune responses. While the published research focuses on SARS-CoV-2 antibodies, the underlying technology platform could potentially be adapted for detection of antibodies against other pathogens or antigens.

How does antibody avidity evolve over time after infection, and what are the implications?

Research using the TOP-Plus platform has revealed a critical but counterintuitive dynamic in antibody responses: while total antibody (TAb) levels and neutralization activity (measured by SNAb) decrease between 1.3 and 6.2 months after infection, antibody avidity increases significantly (P < 0.0001) . This finding has important implications for understanding long-term immunity.

This finding challenges simplistic interpretations of declining antibody titers as evidence of waning immunity, suggesting instead that the immune system undergoes qualitative improvements in antibody binding strength that may be equally important for protection.

What differences exist in antibody avidity between naturally infected and vaccinated individuals?

One of the most significant findings from TOP-Plus testing is that antibody avidity in SARS-CoV-2 vaccinated individuals (measured at a median of 28 days after vaccination) was comparable to the measured antibody avidity in naturally infected individuals (measured at a median of 26 days after infection) .

This finding suggests that vaccination can induce antibody responses with similar qualitative characteristics to natural infection, at least in terms of the strength of antibody binding to target antigens. This is particularly important for understanding the protective efficacy of vaccines and may help explain why vaccines can provide robust protection despite sometimes inducing different quantitative antibody profiles than natural infection.

For researchers studying vaccine immunology, these results suggest that avidity measurements should be incorporated into vaccine evaluation protocols alongside traditional measures of antibody titers and neutralization.

How can TOP-Plus data inform antibody engineering for therapeutic applications?

When developing therapeutic antibodies or antibody-drug conjugates (ADCs), understanding antibody binding characteristics is crucial for efficacy. The TOP-Plus platform's ability to measure both antibody titers and avidity provides valuable insights for antibody engineering and optimization.

For antibody-drug conjugates, which combine monoclonal antibodies with potent anti-cancer agents via chemical linkers, the binding strength (avidity) of the antibody component to its target is critical for therapeutic efficacy . TOP-Plus data could help researchers:

• Select antibody candidates with optimal binding characteristics

• Monitor changes in binding properties during manufacturing processes

• Develop quality control metrics based on avidity measurements

• Predict in vivo performance based on avidity profiles

This application bridges fundamental antibody research with therapeutic development, particularly for cancer treatments that rely on targeted antibody technologies.

What are the key methodological considerations when designing experiments with TOP-Plus?

When designing experiments using the TOP-Plus platform, researchers should consider several methodological factors:

• Time points for sampling: Based on the observation that antibody avidity increases significantly over time while titers decrease, longitudinal sampling strategies should be carefully planned to capture these dynamics. The published research used 1.3 and 6.2 months post-infection as key timepoints .

• Control samples: Include appropriate positive and negative controls, as well as reference standards for calibration of the assay and inter-assay comparisons.

• Sample storage and handling: As with any antibody assay, proper sample collection, processing, and storage protocols should be established to maintain antibody integrity.

• Parallel assays: Consider running parallel assays using traditional methods (e.g., Bio-Layer Interferometry for avidity) on a subset of samples to validate TOP-Plus results, especially when implementing the platform for new applications.

• Statistical power: Ensure sufficient sample sizes to detect significant changes in avidity and other parameters, particularly for longitudinal studies where inter-individual variation may be substantial.

How can researchers optimize experimental conditions for antibody avidity assessment?

To optimize experimental conditions for antibody avidity assessment using TOP-Plus, researchers should consider:

• Antigen selection and coating: The choice and quality of antigens used in the assay will directly impact avidity measurements. For SARS-CoV-2 studies, carefully selected viral antigens that represent relevant epitopes should be used.

• Buffer conditions: Optimize buffer compositions to ensure specific antibody-antigen interactions while minimizing non-specific binding.

• Incubation times and temperatures: These parameters may affect the equilibrium of antibody-antigen binding and should be standardized and validated.

• Chaotropic agent concentration: For avidity determination, the concentration of chaotropic agents (used to disrupt weak antibody-antigen interactions) should be carefully titrated to provide optimal discrimination between high and low avidity antibodies.

• Signal detection parameters: Calibrate and optimize the signal detection settings of the biosensor platform to ensure linearity across the relevant range of avidity measurements.

These optimizations should follow design of experiments (DOE) approaches as used in other antibody research contexts, which allow for systematic evaluation of multiple parameters simultaneously .

How should researchers interpret seemingly contradictory data between antibody levels and avidity?

When faced with seemingly contradictory data showing decreasing antibody levels but increasing avidity, researchers should consider the following interpretive framework:

• Immune maturation perspective: The inverse relationship between quantity and quality often reflects normal immune maturation, where initial high-quantity, low-quality antibody responses evolve toward lower-quantity, higher-quality responses through affinity maturation processes.

• Functional implications: Rather than focusing solely on either metric in isolation, evaluate the combined functional impact. Higher avidity antibodies may achieve equivalent neutralization or protection at lower concentrations.

• Correlates of protection: Analyze how the observed patterns relate to clinical or functional correlates of protection. In some cases, avidity may be a better predictor of protection than raw antibody titers.

• Population heterogeneity: Consider whether the observed patterns are consistent across all subjects or whether particular subgroups (e.g., by age, sex, or disease severity) show different relationships between titer and avidity.

• Statistical validation: Apply appropriate statistical methods to confirm that both the decreasing titers and increasing avidity are statistically significant trends rather than artifacts of measurement variability.

The research using TOP-Plus clearly demonstrated this phenomenon with SARS-CoV-2 antibodies, showing statistically significant increases in avidity (P < 0.0001) despite decreasing TAb and neutralization activity .

What statistical approaches are recommended for analyzing longitudinal antibody avidity data?

For analyzing longitudinal antibody avidity data generated by TOP-Plus, researchers should consider these statistical approaches:

• Paired analysis methods: Since the same individuals are measured at multiple timepoints, paired statistical tests (e.g., paired t-tests or Wilcoxon signed-rank tests) are appropriate for comparing avidity at different timepoints.

• Mixed effects models: These models can account for both fixed effects (e.g., time post-infection, vaccination status) and random effects (individual variation) when analyzing longitudinal data.

• Correlation analysis: Methods such as Pearson or Spearman correlation can assess relationships between different antibody parameters (e.g., titer vs. avidity) and how these relationships change over time.

• Multivariate approaches: Consider techniques like principal component analysis (PCA) or partial least squares (PLS) regression to handle the multi-parameter data generated by TOP-Plus and identify patterns across multiple antibody characteristics.

• Survival analysis: When connecting antibody parameters to clinical outcomes, survival analysis techniques can help determine whether certain avidity thresholds predict protection from disease.

The research with TOP-Plus successfully employed statistical analysis to demonstrate the significant increase in antibody avidity over time (P < 0.0001), validating the platform's utility for longitudinal studies .

How can TOP-Plus be integrated into vaccine development research?

TOP-Plus offers several valuable applications for vaccine development research:

• Comparative vaccine evaluation: The platform can be used to compare antibody responses induced by different vaccine candidates, not just in terms of antibody titers but also avidity and functional characteristics.

• Adjuvant assessment: Researchers can evaluate how different adjuvants affect antibody quality (avidity) in addition to quantity, potentially identifying formulations that promote rapid development of high-avidity antibodies.

• Durability prediction: By measuring both titers and avidity over time, researchers may identify early signatures that predict long-term antibody persistence and protection.

• Correlates of protection studies: The multi-parameter data from TOP-Plus can be analyzed to identify which antibody characteristics (titer, isotype, avidity, etc.) best correlate with protection from disease.

• Population-specific responses: The platform can help characterize how different demographic groups respond to vaccination in terms of antibody quality, potentially informing personalized vaccination strategies.

The study results showing comparable avidity between vaccinated and naturally infected individuals highlight the potential of TOP-Plus for vaccine evaluation and optimization .

What are the potential applications of TOP-Plus in antibody-drug conjugate research?

Antibody-drug conjugates (ADCs) represent an important class of biopharmaceuticals that combine the targeting specificity of monoclonal antibodies with the cytotoxic potency of anti-cancer agents . TOP-Plus methodology could enhance ADC research in several ways:

• Antibody selection: The platform could help researchers select antibody candidates with optimal avidity profiles for ADC development, potentially improving tumor targeting and retention.

• Process optimization: As noted in the context of ADC development, Design of Experiments (DOE) approaches are essential for process optimization . TOP-Plus could be incorporated into such frameworks to monitor how manufacturing conditions affect antibody binding characteristics.

• Quality control: The platform could serve as a quality control tool to ensure consistent antibody binding properties across manufacturing batches of ADCs.

• Structure-function relationships: By correlating antibody avidity with ADC efficacy, researchers could gain insights into how binding properties influence drug delivery and therapeutic outcomes.

• Stability assessment: TOP-Plus could help monitor changes in antibody binding properties during storage or after conjugation to cytotoxic payloads, ensuring that the manufacturing process doesn't compromise antibody functionality.

These applications align with the biopharmaceutical industry's need for robust analytical tools to support the development of complex biological therapeutics like ADCs .